Year: 2022
Type: review
Abstract: The gaps between the complex nature of cancer and therapeutics have been narrowed down due to extensive research in molecular oncology. Despite gathering massive insight into the mysteries of tumor heterogeneity and the molecular framework of tumor cells, therapy resistance and adverse side effects of current therapeutic remain the major challenge. This has shifted the attention towards therapeutics with less toxicity and high efficacy. Myricetin a natural flavonoid has been under the spotlight for its anti-cancer, anti-oxidant, and anti-inflammatory properties. The cutting-edge molecular techniques have shed light on the interplay between myricetin and dysregulated signaling cascades in cancer progression, invasion, and metastasis. However, there are limited data available regarding the nano-delivery platforms composed of myricetin in cancer. In this review, we have provided a comprehensive detail of myricetin-mediated regulation of different cellular pathways, its implications in cancer prevention, preclinical and clinical trials, and its current available nano-formulations for the treatment of various cancers.
Source: Cancer Cell International
Institutions: Lahore Garrison University, National University of Sciences and Technology, Universidad de La Frontera, Universidad Santo Tomás, Lanzhou University, University of Sialkot, University of Veterinary and Animal Sciences, Balochistan University of Information Technology, Engineering and Management Sciences, University of Health Sciences Lahore, University of Medicine and Pharmacy of Craiova, University of Craiova, Universidad del Azuay, Queen Elizabeth Hospital
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,790
OpenAlex ID: W4288447024